Q32 Bio Books $1.2 Million Expense On Half Of 762,000 Employee Stock Units; Other Half Has No Target
The financing half of the July award vested once the cash was raised, while the clinical half is not yet counted as granted.
Q32 Bio, a clinical-stage biotech developing the alopecia areata drug bempikibart, booked $1.2 million in third-quarter expense for the financing-linked portion of a 762,000-unit employee stock award, according to its 10-Q filed Wednesday. The other half, tied to a clinical milestone, has no approved target and has not been counted as granted.
Two halves, two accounting treatments
The board approved the performance-based restricted stock units on July 6, 2026, for certain employees. Vesting runs over twelve equal quarterly installments starting July 1, 2026, contingent on continued service and performance conditions. Half the units depend on a financing milestone and half on a clinical one.
The financing milestone was achieved in July 2026, and the $1.2 million charge falls in the quarter ended September 30.
For the clinical units, the performance condition had not been approved as of September 30, so the units were not considered granted. That condition requires sign-off from the board or compensation committee, so the awards count as unauthorized and carry no recognized expense. Valuation waits until a clinical milestone is approved.
Stock pay climbs alongside the cash pile
Stock-based compensation was $6.1 million for the first nine months of 2026, against $3.8 million a year earlier. For the third quarter alone it was about $2.9 million, up from $1.2 million.
The award landed after a run of financings: a registered direct offering in February at $3.90 a share, a private placement at $8.00 a share in May, and a public offering at $18.25 a share completed July 16, with net proceeds of $187.5 million. Cash stood at $289.6 million at September 30, which management says should last through topline Phase 3 results of a planned registration-directed program.
Shares outstanding reached 29,892,127 at September 30, up from 23,736,600 at June 30, with pre-funded warrants for 6,107,160 more shares unexercised.
The business behind the award
Q32 Bio develops biologics, drugs made from living cells, to restore immune balance in alopecia areata and other autoimmune diseases. Its lead candidate, bempikibart, is in a Phase 2a trial; Part B enrolled 33 patients, and the company has dosed the drug in over 150 participants overall.
Q32 Bio says it intends to start a registration-directed program in the first half of 2027, after regulatory discussions planned for the fourth quarter of 2026. The prior quarterly report carried none of the unit-award language. The company reported a third-quarter net loss of $8.9 million, or $0.26 a share, against $7.4 million a year earlier.
The clinical units stay off the books until the board or compensation committee approves a milestone, and the company's own regulatory talks are slated for the fourth quarter of 2026.
Sources
- 10-Q Filing — Q32 Bio (QTTB) — SEC EDGAR
- 10-Q Filing — Q32 Bio (QTTB), Q2 FY2026 filed 2026-08-05 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, qttb-ex99_1.htm) — Q32 Bio, filed 2026-11-04 — SEC EDGAR